⚕ GalenOps field
←

SITE013-0245

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2022-12-13

AEs
5
Serious
0
Dropout signal
–

Adverse events

severe assessed

Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-02-24 (study day 62); relationship: not assessed

mild assessed

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-03-28 (study day 94); relationship: not assessed

severe assessed

Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-04-07 (study day 104); relationship: Y

moderate assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-12-28 (study day 369); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-01-09 (study day 381); relationship: Y

Data queries

No data queries.